ZA986593B - A method for the treatment of staphylococcal disease - Google Patents

A method for the treatment of staphylococcal disease

Info

Publication number
ZA986593B
ZA986593B ZA986593A ZA986593A ZA986593B ZA 986593 B ZA986593 B ZA 986593B ZA 986593 A ZA986593 A ZA 986593A ZA 986593 A ZA986593 A ZA 986593A ZA 986593 B ZA986593 B ZA 986593B
Authority
ZA
South Africa
Prior art keywords
lysostaphin
staphylococcal
treatment
staphylococcal disease
penicillins
Prior art date
Application number
ZA986593A
Other languages
English (en)
Inventor
Beth P Goldstein
Michael W Climo
Richard P Novick
Gordon L Archer
Original Assignee
Ambi Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambi Inc filed Critical Ambi Inc
Publication of ZA986593B publication Critical patent/ZA986593B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24075—Lysostaphin (3.4.24.75)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA986593A 1997-07-23 1998-07-23 A method for the treatment of staphylococcal disease ZA986593B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5347097P 1997-07-23 1997-07-23

Publications (1)

Publication Number Publication Date
ZA986593B true ZA986593B (en) 1999-02-04

Family

ID=21984478

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA986593A ZA986593B (en) 1997-07-23 1998-07-23 A method for the treatment of staphylococcal disease

Country Status (20)

Country Link
US (1) US20020006406A1 (no)
EP (1) EP1001804B1 (no)
JP (1) JP2001510805A (no)
KR (1) KR20010022237A (no)
CN (1) CN1269727A (no)
AT (1) ATE316794T1 (no)
AU (1) AU754806B2 (no)
BR (1) BR9811535A (no)
CA (1) CA2297083C (no)
DE (1) DE69833377T2 (no)
HU (1) HUP0002662A3 (no)
IL (1) IL134056A0 (no)
NO (1) NO320884B1 (no)
NZ (1) NZ502359A (no)
PL (1) PL338178A1 (no)
RU (1) RU2234940C2 (no)
SK (1) SK732000A3 (no)
TW (1) TWI235656B (no)
WO (1) WO1999004809A1 (no)
ZA (1) ZA986593B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056954A (en) * 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US6428784B1 (en) 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US6277399B1 (en) 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6569830B1 (en) * 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
WO2001082945A2 (en) * 2000-04-28 2001-11-08 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
BR0308285A (pt) * 2002-03-26 2005-04-12 Biosynexus Inc Ruptura de biofilmes bacterianos por meio de enzimas
WO2004050846A2 (en) * 2002-12-02 2004-06-17 Biosynexus Incorporated Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines
WO2004052308A2 (en) * 2002-12-10 2004-06-24 Biosynexus Incorporated Topical anti-infective formulations
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
MX2007008358A (es) * 2005-01-10 2007-09-06 Nabi Biopharmaceuticals Metodo para tratar la infeccion con staphylococcus aureus.
WO2006110776A2 (en) 2005-04-12 2006-10-19 Nektar Therapeutics Al, Corporation Polyethylene glycol cojugates of antimicrobial agents
EP2004215B1 (en) * 2006-03-31 2010-06-09 The University Court of the University of St. Andrews Anti-microbial compositions comprising a cationic peptide and a glycylglycine endopeptidase
WO2007130655A2 (en) 2006-05-05 2007-11-15 Gangagen, Inc. Phage derived antimicrobial activities
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
WO2009150171A1 (en) * 2008-06-10 2009-12-17 Profos Ag Method of treatment of inflammatory diseases
CN113717964A (zh) 2013-08-06 2021-11-30 达特茅斯学院理事会 非糖基化溶葡球菌素变体蛋白
RU2572341C2 (ru) * 2013-09-20 2016-01-10 Федеральное государственное бюджетное учреждение Научно-исследовательский институт по изысканию новых антибиотиков имени Г.Ф. Гаузе Российской академии медицинских наук (ФГБУ "НИИНА" РАМН) АНТИБИОТИК ИНА 5812, ШТАММ-ПРОДУЦЕНТ Streptomyces roseoflavus ИНА-Ас-5812 И СПОСОБ ПОЛУЧЕНИЯ АНТИБИОТИКА
RU2718554C1 (ru) * 2017-09-25 2020-04-08 Георгий Георгиевич Чумбуридзе Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
US11565024B2 (en) 2017-11-16 2023-01-31 Georgia Tech Research Corporation Lysostaphin containing synthetic hydrogel carriers for bone repair
CN110917339B (zh) * 2019-12-27 2023-07-07 遵义医学院附属医院 一种溶葡萄球菌酶凝胶剂及其在mrsa感染创面中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
AU623864B2 (en) * 1988-08-29 1992-05-28 Applied Microbiology, Inc Method of treating mastitis and other staphylococcal infections

Also Published As

Publication number Publication date
SK732000A3 (en) 2001-03-12
AU754806B2 (en) 2002-11-28
CN1269727A (zh) 2000-10-11
NZ502359A (en) 2005-02-25
TWI235656B (en) 2005-07-11
HUP0002662A2 (hu) 2000-12-28
US20020006406A1 (en) 2002-01-17
WO1999004809A1 (en) 1999-02-04
AU8509598A (en) 1999-02-16
DE69833377T2 (de) 2006-11-16
CA2297083C (en) 2007-10-30
PL338178A1 (en) 2000-10-09
DE69833377D1 (de) 2006-04-13
KR20010022237A (ko) 2001-03-15
NO320884B1 (no) 2006-02-06
NO20000314D0 (no) 2000-01-21
NO20000314L (no) 2000-03-16
ATE316794T1 (de) 2006-02-15
BR9811535A (pt) 2000-08-29
HU0002662D0 (en) 2000-08-28
JP2001510805A (ja) 2001-08-07
EP1001804B1 (en) 2006-02-01
HUP0002662A3 (en) 2003-08-28
CA2297083A1 (en) 1999-02-04
IL134056A0 (en) 2001-04-30
EP1001804A1 (en) 2000-05-24
RU2234940C2 (ru) 2004-08-27

Similar Documents

Publication Publication Date Title
ZA986593B (en) A method for the treatment of staphylococcal disease
WO2002003911A8 (en) Prevention and treatment of alzheimer's disease
CA2370030A1 (en) Sodium channel blocker compositions and the use thereof
MY119375A (en) Treatment of tinnitus using neuroprotective agents
PT806941E (pt) Composicoes anti-bacterianas liposomicas de rigidez baixa
AU2119200A (en) Medicament
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
AU2005099A (en) Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
WO2000012049A3 (en) A method for the treatment of staphylococcal disease
WO2000000214A3 (en) Pharmaceutical preparations for use in combatting or preventing surface infections caused by microorganisms
WO2002005642A3 (en) Synergistic biocidal compositions
AP2002002652A0 (en) The use of azalide antibiotic composition for treating or preventing a bacterial or protozoal infection in mammals.
WO1997018790A3 (en) Therapeutic and diagnostic agents for the treatment of microbial infections
WO2001091796A8 (en) Methods, compounds and compositions for treating gout
AU6633596A (en) Improved therapeutic agents
BG103512A (en) Substituted pyramidine compounds and their application
BG103958A (en) Pharmaceutical compositions of thioxanide and nitazoxanide
AUPP325398A0 (en) Improved method for eradicating h. pylori
HUP0103660A2 (hu) Mikróbaeredetű hialuronsavbontó enzimet tartalmazó gyógyászati készítmény
EP1671644A3 (en) Pharmaceutical compositions containing lysostaphin alone or in combination with an antibiotic for the treatment of staphylococcal infections
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
AU1261601A (en) Treatment of C. difficile toxin B associated conditions
MX9604692A (es) Derivados de quinoxalina para el tratamiento de tinnitus.
WO1995005364A3 (en) Inhibitors of biogenic amine transporters
GEP20033144B (en) Hygromycin A Derivatives as Antibacterial Agents